Whitney Steinmetz is a board-certified family nurse practitioner who provides patient-focused, evidence-based care in gastroenterology and hepatology. She has a passion for improving access to care in rural healthcare environments. Dr. Steinmetz earned her bachelor's of science degree with honors, Magna Cum Laude, at the University of Arizona.

Lisa Catalli is a Nurse Practitioner in the Hepatology Department at the University of California San Francisco and an assistant clinical professor at the UCSF School of Nursing. She holds a Master of Science degree and is currently pursuing a PhD at the UCSF School of Nursing. With over 15 years of experience in Hepatology, Lisa specializes in viral hepatitis and MASLD across the liver disease spectrum, including care for liver transplant recipients.

Melissa Palmer, MD has been a Hepatologist for over 35 years and is an experienced biotech/pharma executive. She is currently CEO of Liver Consulting LLC, consulting exclusively to biotech and pharmaceutical companies on hepatology-related issues such as: innovative trial designs for all liver diseases including metabolic dysfunction-associated steatotic hepatitis (MASH), Hepatitis B and D, primary sclerosing cholangitis (PSC), all aspects of liver disease drug development from pre-IND to NDA, and hepatic impairment studies.

Raúl J. Andrade is Professor of Medicine and Director of the Department of Medicine at the University of Malaga. Head of the Gastroenterology Service, University Hospital. Vice-Director of the Institute of Biomedical Research IBIMA-Plataforma BIONAND. He is the Founder and Director of the Spanish Drug Induced Liver Injury Registry (www.spanishdili.uma.es), of the Spanish Latin-American DILI Network and the Prospective European DILI Registry awarded by the EASL. Chairman of the EASL Clinical Practice Guidelines on Drug Induced Liver Injury.

Dr. Rockey is currently a Distinguished University Professor and Director of the MUSC Digestive Disease Research Center and has active research portfolio's in basic as well as clinical science. His laboratory focuses on mechanisms of liver fibrosis and has coined the field of molecular portal hypertension. He has also been actively involved in clinical research focused on liver fibrosis and portal hypertension. Dr.

Arie Regev, MD, FAASLD <br>Dr. Arie Regev is a gastroenterologist and hepatologist with more than 30 years of experience in the treatment and research of liver diseases. He is the Vice President of Medical Global Patient Safety at Eli Lilly and Company, and he heads Eli Lilly's Safety Advisory Hub. In addition, Dr. Regev is the chair of Eli Lilly's Liver Safety Committee, a role he has held for more than 15 years. <br>Dr. Regev is an associate professor of medicine at the division of gastroenterology and hepatology of Indiana University School of Medicine.

Dr Lewis is Professor of Medicine and Director of Hepatology, Division of Gastroenterology , Medstar Georgetown University Hospital , Washington, DC. He has a long-standing interest in the field of drug-induced liver injury , pharmacovigilance and drug-safety . He currently serves as the Academic Lead for the IQ DILI Consortium , a partnership of academia, industry and FDA with a focus on hepatotoxicity.

Eric Cohen, MD is a Senior Medical Director in Pharmacovigilance at Abbvie Inc. and serves as the Chair of the Liver Internal Safety Advisory Group (ISAG). Dr. Cohen completed his fellowship training in Gastroenterology & Hepatology at Yale New Haven Medical Center (2009) and an advanced fellowship in Transplant Hepatology at Beth Israel Deaconess Medical Center (2010). He is an active member of IQ-DILI and is a key opinion leader in the field of hepatotoxicity.

As a hepatologist and Associate Director in CDER's Office of Pharmacovigilance and Epidemiology, Dr. Avigan has served as an expert consultant at FDA for the evaluation of drug-induced liver injury during the life cycle of drugs and biological agents. Earlier on, Dr. Avigan received his MD from McGill University. After his medical residency and GI fellowship, he trained as an NIH staff fellow and then was on the faculty of Georgetown University where he attended patients and was the principal investigator of NIH-funded grants to elucidate basic mechanisms in cell growth pathways.

I am a Professor of Medicine and Transplant Hepatologist at UCSF. My NIH-funded research focuses on the intersections of HIV, viral hepatitis, and hepatic steatosis.